Companies › Prothya Biosolutions
1 active drug program in 1 registered trial: 1 Phase 2; Hematology; next expected readout Jan 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Human apotransferrin Transferrin replacement protein | TF | Phase 2 | Congenital Atransferrinemia | Jan 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT01797055 | Human apotransferrin | Phase 2 | Congenital Atransferrinemia | Hematology | Jan 2028 |
–
S-INFINITY Pharmaceuticals Imara Shanghai RAAS Blood Products Pharmanutra Vega Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.